On Technology Platform
Chris Ehrlich: Our CER-T platform represents a next-generation approach to cancer immunotherapy. We are engineering T cells with enhanced capabilities to recognize and eliminate tumors more effectively than current approaches.
The key innovation is our chimeric engulfment receptor technology. Unlike traditional CAR-T which relies solely on killing, our approach also enables T cells to engulf and process tumor cells, potentially creating a more durable anti-tumor response.
On Clinical Progress
Q: Where are you in clinical development?
Chris Ehrlich: We are advancing our lead program through clinical trials with encouraging early results. Patient responses have validated our scientific approach, and we are expanding enrollment to further demonstrate safety and efficacy.
Our manufacturing capabilities are also scaling to support clinical and eventual commercial needs. Cell therapy manufacturing is complex, and we have made significant investments in this area.
On Competitive Advantages
Q: How does CER-T compare to other cell therapies?
Chris Ehrlich: We believe CER-T has potential advantages in both efficacy and safety. The dual mechanism of action – killing plus engulfment – may provide more complete tumor elimination. We are also seeing encouraging persistence data that could translate to more durable responses.
On Partnership Strategy
Q: Are you pursuing partnerships?
Chris Ehrlich: We remain open to strategic partnerships that can accelerate our programs. The right partner could provide resources, expertise, and commercial capabilities that complement our technology platform. However, we are disciplined about maintaining value and control of our core assets.